Vincerx Pharma Inc (VINC) concluded trading on Thursday at a closing price of $0.14, with 3.99 million shares of worth about $0.56 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -79.30% during that period and on January 16, 2025 the price saw a loss of about -8.25%. Currently the company’s common shares owned by public are about 31.40M shares, out of which, 28.49M shares are available for trading.
Stock saw a price change of -27.41% in past 5 days and over the past one month there was a price change of -26.65%. Year-to-date (YTD), VINC shares are showing a performance of -46.69% which decreased to -89.14% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.14 but also hit the highest price of $9.37 during that period. The average intraday trading volume for Vincerx Pharma Inc shares is 7.07 million. The stock is currently trading -31.38% below its 20-day simple moving average (SMA20), while that difference is down -42.49% for SMA50 and it goes to -79.99% lower than SMA200.
Vincerx Pharma Inc (NASDAQ: VINC) currently have 31.40M outstanding shares and institutions hold larger chunk of about 30.24% of that.
The stock has a current market capitalization of $5.11M and its 3Y-monthly beta is at 1.19. It has posted earnings per share of -$1.03 in the same period. It has Quick Ratio of 2.17 while making debt-to-equity ratio of 0.18. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for VINC, volatility over the week remained 12.39% while standing at 17.52% over the month.
Stock’s fiscal year EPS is expected to rise by 59.79% while it is estimated to increase by 39.47% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by H.C. Wainwright on January 14, 2022 offering a Buy rating for the stock and assigned a target price of $25 to it. Coverage by Cantor Fitzgerald stated Vincerx Pharma Inc (VINC) stock as an Overweight in their note to investors on December 23, 2021, suggesting a price target of $25 for the stock. On November 01, 2021, SVB Leerink Initiated their recommendations, while on September 13, 2021, Laidlaw Initiated their ratings for the stock with a price target of $30. Stock get a Buy rating from B. Riley Securities on August 25, 2021.
